Figure 1
From: CETSA-based target engagement of taxanes as biomarkers for efficacy and resistance

CETSA shows distinct melt curves for α- and β-tubulin that shift upon drug binding in cancer cells. Schematic overview of the CETSA method (A). Western blot-CETSA shows that the tubulin-binding drugs paclitaxel and vinorelbine (20 µM) produce clear shifts for β-tubulin in K562-cells (B and C). In MCF-7 cells, the two taxanes, paclitaxel and docetaxel (20 µM), produce significant CETSA shifts for both β-tubulin and α-tubulin (D and E). Daunorubicin and cytarabine (negative controls) produced no shift in both β-tubulin and α-tubulin (F and G). All data represent the mean ± S.E.M from independent experiments (n = 5–6 in D and E, and n = 3 in B,C,F and G) and are presented as a percentage of the signal detected at the lowest temperature in each melt curve.